NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Is Up 14.3% After ZELSUVMI At-Home Launch and $5M Milestone Payment
Ligand Pharmaceuticals announced that its partner Pelthos Therapeutics has launched ZELSUVMI (berdazimer) gel, the first FDA-approved at-home treatment for molluscum contagiosum, triggering a US$5 million milestone payment to Ligand.
Ligand now holds a 56% stake in Pelthos and also stands to benefit from future royalties and additional milestone payments tied to ZELSUVMI sales.
We'll examine how the commercial launch of ZELSUVMI could shape Ligand Pharmaceuticals' expanding royalty revenue...